VEGFR

Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis (the formation of the circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature).

B0084-263525
PD173074
219580-11-7
B0084-175350
Ki8751
228559-41-9
B0084-088558
CP-547632
252003-65-9
B0084-409435
Orantinib
252916-29-3
B0084-065081
Sorafenib
284461-73-0
B0084-286440
KRN633
286370-15-8
B0084-065171
288383-20-0
B0084-178779
NVP-ACC789
300842-64-2
B0084-475639
JNJ 17029259
314267-57-7
B0084-461979
Axitinib
319460-85-0
B0084-313239
SU11652
326914-10-7
B0084-108953
Telatinib
332012-40-5
B0084-463630
338992-53-3
B0084-187069
Sunitinib Malate
341031-54-7
B0084-284844
SU 5205
3476-86-6

Background


An overview of VEGFR

Vascular endothelial growth factor (VEGF) is an important signaling protein. Combined with the corresponding vascular endothelial growth factor receptor (VEGFR), it can stimulate the proliferation and migration of endothelial cells through specific signaling pathways, thus facilitating angiogenesis. Therefore, VEGF, VEGFR and their associated downstream signaling pathways can be used as targets for anti-tumor drug action.

Major types of VEGFR

VEGFR can be divided into three types, including VEGFR1, VEGFR2 and VEGFR3. Human VEGFR2 is a receptor containing kinase insertion region expressed on the surface of vascular endothelial cells, whose structure can be divided into three parts, including extracellular region, intracellular region and one transmembrane region.

Inhibition of VEGFR

Afibercept , which is a potent VEGFR blocker, has obtained positive results in clinical Ⅲ study of the second-line regimen for non-small cell lung cancer (NSCLC), which is associated with docetaxel.

VEGFR and diseases

When the tumor has just occurred, and the volume is less than 2 ~ 3 mm, there is no need for angiogenesis, because oxygen and other nutrients can reach the tumor tissue by penetrating the blood vessels that are located next to the tumor tissue. When its volume exceeds 3 mm, the tumor is in anoxic condition. Hypoxia and oncogene can raise the expression of VEGF in tumor cells, and VEGF and hypoxia could further improve the expression of VEGFR-1 and kinase inserted domain containing receptor (KDR). Thus, the tumors induce angiogenesis through VEGF-VEGFR signaling pathways. And the expression of VEGF and VEGFR in many tumor tissues has been found to be higher than normal tissues by using in situ hybridization and immunohistochemical methods, and they are positively correlated with the vascular density of tumor tissue. This shows that the VEGF-VEGFR signal transduction pathway is closely related to tumor angiogenesis and tumor growth. In addition, animal experiments have confirmed that specific VEGF neutralizing antibodies can inhibit new angiogenesis and tumor growth in mouse transplanted tumors, and this antibody has no direct inhibitory effect on tumor cells.